Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Newrabell in Refractory Reflux Esophagitis
NCT01860482Phase 4Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2013
- Primary completion
- May 2015
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gabapentin + methylcobalamin in reflux esophagitis, sponsored by Chong Kun Dang Holdings. Primary endpoint: Time to onset of first 1Day Heartburn free up to 8 weeks. Started Apr 2013; status: completed.
02
Drugs
gabapentin + methylcobalamin
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT01860482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01860482.